Savara, Inc. (SVRA)
4.635
-0.08
(-1.80%)
USD |
NASDAQ |
Nov 13, 16:00
4.68
+0.04
(+0.97%)
After-Hours: 19:59
Savara Gross Profit Margin (Quarterly)
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2020 | 0.00% |
| September 30, 2020 | 0.00% |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | 0.00% |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 |
| Date | Value |
|---|---|
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 | |
| December 31, 2013 | |
| September 30, 2013 | |
| June 30, 2013 | |
| March 31, 2013 | |
| December 31, 2012 | |
| September 30, 2012 | |
| June 30, 2012 | |
| March 31, 2012 | |
| December 31, 2011 | |
| September 30, 2011 | |
| June 30, 2011 | |
| March 31, 2011 | |
| December 31, 2010 | 99.39% |
| September 30, 2010 | |
| June 30, 2010 | |
| March 31, 2010 | |
| December 31, 2009 | |
| September 30, 2009 | |
| June 30, 2009 | |
| March 31, 2009 | 0.00% |
| December 31, 2008 | |
| September 30, 2008 |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 89.75% |
| Alnylam Pharmaceuticals, Inc. | 75.19% |
| Anika Therapeutics, Inc. | 61.57% |
| Vericel Corp. | 73.34% |
| Biogen, Inc. | 63.23% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -105.3% |
| Return on Assets | -79.21% |
| Return on Invested Capital | -87.21% |
| Return on Net Operating Assets | -953.0% |